Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition

Intensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with...

Full description

Bibliographic Details
Main Authors: Heta Lad, Tyler M. Saumur, Margaret S. Herridge, Claudia C. dos Santos, Sunita Mathur, Jane Batt, Penney M. Gilbert
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:https://www.mdpi.com/1422-0067/21/21/7840
id doaj-c58cfa8382fc4ecea9e67e18fed415d5
record_format Article
spelling doaj-c58cfa8382fc4ecea9e67e18fed415d52020-11-25T03:53:58ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672020-10-01217840784010.3390/ijms21217840Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying ConditionHeta Lad0Tyler M. Saumur1Margaret S. Herridge2Claudia C. dos Santos3Sunita Mathur4Jane Batt5Penney M. Gilbert6Institute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, CanadaRehabilitation Sciences Institute, University of Toronto, Toronto, ON M5G 2A2, CanadaDivision of Critical Care Medicine, University Health Network, Toronto, ON M5G 2C4, CanadaKeenan Research Center for Biomedical Science, St. Michael’s Unity Health Toronto, Toronto, ON M5B 1T8, CanadaDepartment of Physical Therapy, University of Toronto, Toronto, ON M5G 1V7, CanadaKeenan Research Center for Biomedical Science, St. Michael’s Unity Health Toronto, Toronto, ON M5B 1T8, CanadaInstitute of Biomedical Engineering, University of Toronto, Toronto, ON M5S 3G9, CanadaIntensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with muscle protein degradation such as the ubiquitin proteasome system and dysregulated autophagy. Furthermore, it is characterized by the preferential loss of myosin, a distinct feature of the condition. While many risk factors for ICUAW have been identified, effective interventions to offset these changes remain elusive. In addition, our understanding of the mechanisms underlying the long-term, sustained weakness observed in a subset of patients after discharge is minimal. Herein, we discuss the various proposed pathways involved in the pathophysiology of ICUAW, with a focus on the mechanisms underpinning skeletal muscle wasting and impaired contractility, and the animal models used to study them. Furthermore, we will explore the contributions of inflammation, steroid use, and paralysis to the development of ICUAW and how it pertains to those with the corona virus disease of 2019 (COVID-19). We then elaborate on interventions tested as a means to offset these decrements in muscle function that occur as a result of critical illness, and we propose new strategies to explore the molecular mechanisms of ICUAW, including serum-related biomarkers and 3D human skeletal muscle culture models.https://www.mdpi.com/1422-0067/21/21/7840muscle atrophycritical illnessintensive care unit-acquired weaknesscritical illness myopathycritical illness polyneuropathyCOVID-19
collection DOAJ
language English
format Article
sources DOAJ
author Heta Lad
Tyler M. Saumur
Margaret S. Herridge
Claudia C. dos Santos
Sunita Mathur
Jane Batt
Penney M. Gilbert
spellingShingle Heta Lad
Tyler M. Saumur
Margaret S. Herridge
Claudia C. dos Santos
Sunita Mathur
Jane Batt
Penney M. Gilbert
Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
International Journal of Molecular Sciences
muscle atrophy
critical illness
intensive care unit-acquired weakness
critical illness myopathy
critical illness polyneuropathy
COVID-19
author_facet Heta Lad
Tyler M. Saumur
Margaret S. Herridge
Claudia C. dos Santos
Sunita Mathur
Jane Batt
Penney M. Gilbert
author_sort Heta Lad
title Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
title_short Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
title_full Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
title_fullStr Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
title_full_unstemmed Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition
title_sort intensive care unit-acquired weakness: not just another muscle atrophying condition
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2020-10-01
description Intensive care unit-acquired weakness (ICUAW) occurs in critically ill patients stemming from the critical illness itself, and results in sustained disability long after the ICU stay. Weakness can be attributed to muscle wasting, impaired contractility, neuropathy, and major pathways associated with muscle protein degradation such as the ubiquitin proteasome system and dysregulated autophagy. Furthermore, it is characterized by the preferential loss of myosin, a distinct feature of the condition. While many risk factors for ICUAW have been identified, effective interventions to offset these changes remain elusive. In addition, our understanding of the mechanisms underlying the long-term, sustained weakness observed in a subset of patients after discharge is minimal. Herein, we discuss the various proposed pathways involved in the pathophysiology of ICUAW, with a focus on the mechanisms underpinning skeletal muscle wasting and impaired contractility, and the animal models used to study them. Furthermore, we will explore the contributions of inflammation, steroid use, and paralysis to the development of ICUAW and how it pertains to those with the corona virus disease of 2019 (COVID-19). We then elaborate on interventions tested as a means to offset these decrements in muscle function that occur as a result of critical illness, and we propose new strategies to explore the molecular mechanisms of ICUAW, including serum-related biomarkers and 3D human skeletal muscle culture models.
topic muscle atrophy
critical illness
intensive care unit-acquired weakness
critical illness myopathy
critical illness polyneuropathy
COVID-19
url https://www.mdpi.com/1422-0067/21/21/7840
work_keys_str_mv AT hetalad intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT tylermsaumur intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT margaretsherridge intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT claudiacdossantos intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT sunitamathur intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT janebatt intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
AT penneymgilbert intensivecareunitacquiredweaknessnotjustanothermuscleatrophyingcondition
_version_ 1724475573634334720